A road map for the treatment of pediatric diffuse midline glioma.

Document Type

Article

Publication Date

1-8-2024

Identifier

DOI: 10.1016/j.ccell.2023.11.002

Abstract

Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include immune and brain-specific components; (2) collaboration among researchers, clinicians, and industry to integrate patient-derived data through sharing, transparency, and regulatory considerations; and (3) streamlining clinical efforts including biopsy, CNS-drug delivery, endpoint determination, and response monitoring. We highlight the importance of comprehensive collaboration to advance the understanding, diagnostics, and therapeutics for DMGs.

Journal Title

Cancer cell

Volume

42

Issue

1

First Page

1

Last Page

5

MeSH Keywords

Humans; Child; Brain Neoplasms; Glioma; Mutation; Brain; Biopsy

Keywords

Brain Neoplasms; Glioma; Mutation; Brain; Biopsy

Link to Full Text
Library Record

Share

COinS